<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831544</url>
  </required_header>
  <id_info>
    <org_study_id>HW-MVAD-01</org_study_id>
    <nct_id>NCT01831544</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the HeartWare MVAD® System (MVAdvantage)</brief_title>
  <official_title>Multi Center, Prospective, Non-Randomized, Single-Arm Trial Evaluating the Clinical Safety and Performance Of the HeartWare MVAD® System For the Treatment of Advanced Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, prospective, non-randomized, single-arm trial will investigate the safety
      and performance of the HeartWare® Miniaturized Ventricular Assist Device (MVAD®) system over
      24 months in subjects with advanced heart failure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, prospective, non-randomized, single-arm trial will investigate the safety
      and performance of the Miniaturized Ventricular Assist Device (MVAD®) system over 24 months
      in subjects with advanced heart failure. The primary endpoint is survival at 6 months
      presented as a simple proportion (subjects alive on the MVAD® pump divided by endpoint
      eligible subjects). Secondary endpoints include the incidence of bleeding, incidence of major
      infections (per INTERMACS definitions), time to death, incidence of all device failures and
      device malfunctions, Health Status improvement, and Functional status improvement. Safety
      measures will include the frequency and rates of adverse events, overall and for each
      specific event, which will be collected throughout VAD support.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">May 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Six month</time_frame>
    <description>Primary Endpoint: survival at 6 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 6 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Two years</time_frame>
    <description>Survival at 24 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 24 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Overall Survival (Time to Death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Bleeding</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Incidence of major bleeding, per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All Device Failures and Device Malfunctions</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Incidence of all device failures and device malfunctions per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Infection</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Incidence of major infection, per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Neurological Dysfunction</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Incidence of neurological dysfunction per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status Change, as Measured by KCCQ and EuroQol EQ-5D-5L</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Health Status change, as measured by KCCQ and EuroQol EQ-5D-5L
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status Change, as Measured by NYHA and 6-minute Walk</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Functional status change, as measured by NYHA and 6-minute walk
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Rates of Adverse Events(AEs)</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Frequency and rates of adverse events(AEs) throughout VAD support per INTERMACS Definition
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Operative Time and Initial Hospital Stay</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Length of operative time and initial hospital stay
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-Hospitalizations</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Re-Hospitalizations, excluding planned procedures
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplantations</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Transplantations
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explants</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Explants
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>MVAD® Pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implant of HeartWare MVAD® System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartWare MVAD® System</intervention_name>
    <description>The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
    <arm_group_label>MVAD® Pump</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be ≥18 years of age at consent

          2. Subjects with advanced heart failure symptoms (Class IIIB or IV) who meet one of the
             following):

               1. on optimal medical management including dietary salt restriction and diuretics,
                  for at least 45 out of the last 60 days and are failing to respond; or

               2. in Class III or Class IV heart failure for at least 14 days and dependent on
                  intra-aortic balloon pump (IABP) and/or inotropes.

          3. Left ventricular ejection fraction ≤25%.

          4. Female subjects of childbearing potential must agree to use adequate contraceptive
             precautions (defined as oral contraceptives, intrauterine devices, surgical
             contraceptives or a combination of condom and spermicide) for the duration of the
             study.

          5. The subject has signed the informed consent form.

        Exclusion Criteria:

          1. Body Mass Index (BMI) &gt; 47.

          2. Body Surface Area (BSA) &lt; 1.0 m2.

          3. Partial or full mechanical circulatory support within thirty days of implant.

          4. Existence of any ongoing mechanical circulatory support (MCS) other than an
             intra-aortic balloon pump (IABP) or TandemHeart PTVA®.

          5. Prior cardiac transplant or cardiomyoplasty.

          6. History of confirmed, untreated abdominal or thoracic aortic aneurysm (diameter &gt; 5
             cm).

          7. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave
             changes on the electrocardiogram (ECG), diagnostic biomarkers, ongoing pain and
             hemodynamic abnormalities.

          8. On ventilator support for &gt; 72 hours within the four days immediately prior to
             implant.

          9. Pulmonary embolus within three weeks of implant as documented by computed tomography
             (CT) scan or nuclear scan.

         10. Symptomatic cerebrovascular disease, stroke within 180 days of implant or &gt; 80%
             stenosis of carotid or cranial vessels in the absence of confirmed collateral
             circulation

         11. Uncorrected moderate to severe aortic insufficiency.

         12. Severe right ventricular failure as defined by the anticipated need for extracorporeal
             membrane oxygenation (ECMO) at the time of screening.

         13. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and
             laboratory testing, including but not limited to, continued positive cultures,
             elevated temperature and white blood cell (WBC) count, hypotension, tachycardia,
             generalized malaise despite appropriate antibiotic, antiviral or antifungal treatment.

         14. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count &lt;
             75,000, International Normalized Ratio (INR) &gt; 2.0 or Partial Thromboplastin Time
             (PTT) &gt; 2.5 times control in the absence of anticoagulation therapy).

         15. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or
             postoperative therapy that the investigator may administer based upon the subject's
             health status.

         16. Serum creatinine &gt; 3.0 mg/dL within 72 hours of implant or requiring dialysis.

         17. Specific liver enzymes [Aspartate Aminotransferase (AST) (SGOT), and Alanine
             Aminotransferase (ALT) (SGPT)] &gt; 3 times upper limit of normal within 72 hours of
             implant.

         18. A total bilirubin &gt; 3 mg/dL within 72 hours of implant, or biopsy proven liver
             cirrhosis or portal hypertension.

         19. Pulmonary vascular resistance (PVR) is demonstrated to be unresponsive to
             pharmacological manipulation.

         20. Subjects with a mechanical heart valve.

         21. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease,
             obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or
             restrictive cardiomyopathy.

         22. History of severe COPD or severe restrictive lung disease (e.g. FEV1 &lt; 50% predicted
             value).

         23. Participation in any other trial involving investigational drugs or devices within 4
             weeks prior to screening and last visit of the trial.

         24. Severe illness, other than heart disease, which would limit survival to &lt; 3 years.

         25. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities.

         26. Pregnancy and breast feeding.

         27. Psychiatric disease, irreversible cognitive dysfunction or psychosocial issues that
             are likely to impair compliance with the CIP and LVAD.

         28. Subject unwilling or unable to comply with trial requirements.

         29. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of
             the investigator.

         30. Employees of the investigator or trial site, with direct involvement in this trial or
             other trials under the direction of the investigator or trial site, as well as family
             members or employees of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Vincents Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University AKH Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitalier Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart and Diabetes Center NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Heart Institute Berlin DHZB</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duesseldorf University Hospital</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Hamburg Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School MHH</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE77DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS Foundation</name>
      <address>
        <city>Papworth Everard</city>
        <zip>CB233RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <results_first_submitted>March 24, 2020</results_first_submitted>
  <results_first_submitted_qc>March 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2020</results_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 11, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT01831544/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT01831544/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MVAD® Pump</title>
          <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Still on original MVAD device</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MVAD® Pump</title>
          <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="14.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177.3" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.5" spread="14.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101" spread="15.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.9" spread="10.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intermacs Patient Profile</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 - Critical cardiogenic shock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - Progressive decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 - Inotrope dependent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 - Resting symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - Exertion intolerant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - Exertion limited</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 - Advanced NYHA III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.2" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area</title>
          <units>m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>Primary Endpoint: survival at 6 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 6 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
        <time_frame>Six month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Primary Endpoint: survival at 6 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 6 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Survival at 24 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 24 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
        <time_frame>Two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Survival at 24 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 24 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Overall Survival (Time to Death)</description>
        <time_frame>Six month and two years</time_frame>
        <population>One participant died</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Overall Survival (Time to Death)</description>
          <population>One participant died</population>
          <units>months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Bleeding</title>
        <description>Incidence of major bleeding, per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Bleeding</title>
          <description>Incidence of major bleeding, per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All Device Failures and Device Malfunctions</title>
        <description>Incidence of all device failures and device malfunctions per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All Device Failures and Device Malfunctions</title>
          <description>Incidence of all device failures and device malfunctions per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Infection</title>
        <description>Incidence of major infection, per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Infection</title>
          <description>Incidence of major infection, per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Neurological Dysfunction</title>
        <description>Incidence of neurological dysfunction per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Neurological Dysfunction</title>
          <description>Incidence of neurological dysfunction per INTERMACS definition
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Status Change, as Measured by KCCQ and EuroQol EQ-5D-5L</title>
        <description>Health Status change, as measured by KCCQ and EuroQol EQ-5D-5L
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Health Status Change, as Measured by KCCQ and EuroQol EQ-5D-5L</title>
          <description>Health Status change, as measured by KCCQ and EuroQol EQ-5D-5L
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status Change, as Measured by NYHA and 6-minute Walk</title>
        <description>Functional status change, as measured by NYHA and 6-minute walk
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status Change, as Measured by NYHA and 6-minute Walk</title>
          <description>Functional status change, as measured by NYHA and 6-minute walk
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Rates of Adverse Events(AEs)</title>
        <description>Frequency and rates of adverse events(AEs) throughout VAD support per INTERMACS Definition
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Rates of Adverse Events(AEs)</title>
          <description>Frequency and rates of adverse events(AEs) throughout VAD support per INTERMACS Definition
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Operative Time and Initial Hospital Stay</title>
        <description>Length of operative time and initial hospital stay
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Operative Time and Initial Hospital Stay</title>
          <description>Length of operative time and initial hospital stay
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Re-Hospitalizations</title>
        <description>Re-Hospitalizations, excluding planned procedures
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Re-Hospitalizations</title>
          <description>Re-Hospitalizations, excluding planned procedures
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplantations</title>
        <description>Transplantations
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Transplantations</title>
          <description>Transplantations
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Explants</title>
        <description>Explants
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Explants</title>
          <description>Explants
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion: an average of 20.8 months but up to 2 years post implant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MVAD® Pump</title>
          <description>Implant of HeartWare MVAD® System
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Intermacs 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Major Bleeding</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pericardial Fluid Collection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Major Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Malfunction/Failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Non-CNS Thromboembolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Intermacs 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="27" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Major Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device malfunction/failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the early suspension of enrollments, the target sample size of 57 was not reached. Fewer than 15 subjects were enrolled, thus no analysis was done.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Methee Schreuder</name_or_title>
      <organization>Medtronic</organization>
      <phone>+31611597388</phone>
      <email>methee.schreuder@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

